Our news - IRCCS

Events Published on 04/11/2025

SAVE THE DATE Post-regional ASH: March 6, 2026

Provisional program, subject to change: 9:00 AM: Welcome of participants: Prof. Bachy, Dr. Golfier 9:15 AM: Updates in allogeneic transplantation: Dr. Labussière, Prof. Bay, Dr. Cornillon 9:45 AM: Updates in AML and ALL: Dr. Heiblig, Dr. Carre, Dr. Balsat Coffee break 11:15 AM: Updates in myelodysplastic syndromes: Dr. Fossard, Prof. Park 11:45 AM: Updates in lymphomas: Prof. Ghesquieres, Dr. Carras, Dr. Sesques, Dr. Fouillet Lunch break 2:00 PM: Updates in benign hematology: Prof. Garban 2:15 PM: Updates in PNH, aplasias, and myeloproliferative syndromes: Dr. Alcazer, Dr. Barraco 3:15 PM: Updates in multiple myeloma: Dr. Karlin, DR. Lazareth, DR. Chalayer Coffee Break 3:45 PM: News in the LLC: Prof. Guiez, Dr. Ferrant 4:15 PM: Conclusions and Acknowledgments: Prof. Bachy

Studies on data Published on 30/06/2025

Presentation of 2 posters at the LUGANO 2025 congress

Pr. Hervé GHESQUIÈRES: Synthetic control arm from clinical trial and real-world cohorts from LYSA group for untreated older classical Hodgkin lymphoma for innovative clinical trial designs Dr. Estelle BOURBON: Impact of Response to Holding/Bridging Therapy in Second-line DLBCL Patients Treated with Axicabtagene ciloleucel: a LYSA Study from the French DESCAR-T Registry

Clinical trials Events Published on 30/06/2025

Pr Hervé GHESQUIÈRES in the spotlight: oral participation at LUGANO 2025

Final analysis of the Lysa Phase II TIRHOL BGB-A317-210 study: TISLELIZUMAB, an anti-PD-1 antibody in patients with relapsed or refractory classical Hodgkin lymphoma.

Clinical trials Events Published on 30/06/2025

Pr Emmanuel BACHY : communication at LUGANO congress

Extended follow-up results for GOLCADOMIDE + rituximab in patients with relapsed/refractory (R/R) DLBCL in the Phase 1/2 CC-99282-NHL-001 study (NCT03930953).

Clinical trials Events Published on 30/06/2025

Professor Emmanuel BACHY oral communication during the LUGANO congress

Primary results for patients with relapsed/refractory (R/R) FL treated with valemetostat in the open-label, single-arm, phase 2 VALYM study

Events Published on 05/05/2025

It all started with clinical trials…

Leaders in CAR-T cell treatment, HCL treats its 500th adult patient with this revolutionary therapy

Clinical trials Published on 01/05/2025

TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomas

Pierre Stephan, Roberta Di Blasi, Louise Roulin, Jean Galtier, Julien Calvani, Veronique Meignin, Marie Donzel, Alexandra Traverse-Glehen, Elsa Poullot, Marie-Cécile Parrens, Vivien Dupont, Alexandra Marquet, Steven Le Gouill , Roch Houot, Francois-Xavier Gros, François Lemonnier, Emmanuel Bachy, Catherine Thieblemont, Pierre Sesques

Studies on data Published on 24/04/2025

Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?

Nicolas Gazeau, David Beauvais, Rémi Tilmont, Micha Srour, Emmanuelle Ferrant, Violaine Safar, Ludovic Fouillet, Pascale Flandrin-Gresta, Nicolas Gower, Paul Chauvet, Nicolas Duployez, Benjamin Podvin, Julie Demaret, Sarah Huet, Pierre Sujobert, Hervé Ghesquières, Gandhi Damaj, Emmanuel Bachy, Franck Morschhauser, Ibrahim Yakoub-Agha, Maël Heiblig, Pierre Sesques